{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-029611","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.624788+00:00","generated_at":"2026-06-04T23:13:31.372419+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Revelation presents positive preclinical Gemini data for AKI; Phase 1 initiated","bullets":["Gemini (PHAD) significantly reduced serum BUN, creatinine, and urine CRP in rat AKI model at 0.35 mg/kg (p<0.05).","Reduced cortical/medullary tubular necrosis and neutrophilic inflammation at 0.35 mg/kg dose.","Phase 1 clinical studies for Gemini initiated in February/March 2024.","Data presented at the 29th Intl Conference on Advances in Critical Care Nephrology on March 12, 2024.","Gemini is a synthetic TLR4 agonist that preconditions innate immunity to attenuate pro-inflammatory response."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-029611","json":"https://secwatch.observer/filing/0000950170-24-029611.json","markdown":"https://secwatch.observer/filing/0000950170-24-029611.md","text":"https://secwatch.observer/filing/0000950170-24-029611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024029611/0000950170-24-029611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024029611/revb-20240312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:13:31.372419+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}